Compare Abeona Therapeutics Inc (ABEO) vs American Water Works Company Inc (AWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs American Water Works Company Inc — how do they compare? Abeona Therapeutics Inc trades at $6.67 (market cap $373.32M), while American Water Works Company Inc trades at $134.54 (market cap $26.33B). The key difference: American Water Works Company Inc is far larger — about 70.5× Abeona Therapeutics Inc's market cap, and American Water Works Company Inc pays a 2.66% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AWK | |
|---|---|---|
Market Cap | $373.32M | $26.33B |
Sector | Health | Utilities |
52-Week High | $7.23 | $147.00 |
52-Week Low | $4.17 | $121.13 |
Enterprise Value | $228.22M | $41.89B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AWK trades at $134.82, down 1.49% today, near the consensus price target of $134.50. The stock shows a bullish technical trend with strong moving averages, while recent earnings have been mixed with two misses in the last three quarters. Revenue grew to $5.14B in 2025, with a net income margin of 21.17%, and the company continues strategic acquisitions and infrastructure investments, as seen in recent news (PRNewsWire, June 30, 2026).
Outlook remains stable with analyst consensus leaning buy (46.66% buy ratings), but risks include high debt levels and regulatory pressures. The stock offers steady growth potential through capital investments, though margin pressures and interest expenses could limit upside. Investors should weigh the defensive utility sector appeal against valuation multiples like a P/E of 23.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →
